OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
| Autor: | Kim, T.M., Guarneri, V., Jye, V.P., Khaw, L.B., Yang, J.-J., Wislez, M., Huang, C., Chong Kin, L., Mazieres, J., Tho, L.M., Hayashi, H., Nhung, N., Chia, P.L., De Marinis, F., Raskin, J., Zhou, Q., Finochhiaro, G., Le, X., Tan, D., Brutlach, S., O'Brate, A., Adrian, S., Berghoff, K., Ellers-Lenz, B., Karachaliou, N., Wu, Y.-L. |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology November 2023 18(11) Supplement:S94-S94 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|